Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.
about
Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndromeOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolismOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolismOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosisStroke prevention in atrial fibrillation: latest clinical trials and guidelinesEfficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewProfiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differencesMonitoring anticoagulant therapy with new oral agentsNeuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutionsApixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based reviewDifferential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranManagement of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentratesReversal of target-specific oral anticoagulantsSafety of new oral anticoagulant drugs: a perspectiveAnticoagulation drug therapy: a reviewThe new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literatureDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced ageAnticoagulation in atrial fibrillationAnticoagulants and the propagation phase of thrombin generationClinical research priorities in adult congenital heart diseasePharmacology of argatroban.Direct thrombin inhibitors.New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.Anticoagulation Therapy in Patients with Chronic Kidney Disease.Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyIn situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingDabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsReversal of novel oral anticoagulants in patients with major bleeding.Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBenchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Treatment options for venous thromboembolism: lessons learnt from clinical trials.New options in anticoagulation for the prevention of venous thromboembolism and stroke.
P2860
Q24185813-AEC3B4EE-6694-44E9-A7A0-163A309C8C65Q24187205-35D60F93-25B3-450D-B872-2B50E668897CQ24200864-C4D729A3-1E00-489B-92D4-A7582ADF27CFQ24200867-B0280FFC-C23B-47B5-A90F-6F0D1829442FQ24628390-7CE862EB-95F6-409E-8BAB-C85F099A6DCFQ26749141-3F888210-80C3-4C42-9486-B7B9E9DAFAC0Q26765949-137F1F11-BFF0-4809-8E7D-D9D1224B0A83Q26766354-E1C1A064-1E98-44CF-9A4B-A8C04E0F3153Q26771728-C6BA20D5-69E8-444E-9921-BA6BACEC639AQ26782931-B8F0CB57-4CBE-44E0-80C2-3E432359D397Q26783455-E456252A-3CB8-4385-AC01-62BA50A9E09EQ26799710-FEE2C287-B5C4-4091-9352-EE9F02D10F5DQ26822974-A121BE04-6E42-40BC-A882-8368B3065E05Q27003866-F7D613D4-03CB-4EB5-8F3A-5A47B94D81C3Q27016072-79275FA8-490E-44D1-9386-DCD81A07B613Q27021871-BC126329-43CB-48AC-BAE8-0AC96509C7A5Q27497485-8095438C-8AE2-4055-AC6B-0A40EFC9E323Q28079930-D134A345-47D8-41FC-A5E4-8D41403B88A9Q28315636-2C39995D-F538-4D67-B76D-BC2439480210Q28742536-AD92E22D-CC60-4A6E-9C3E-D1F0AFF76302Q30418760-73944759-382E-4406-BAB5-D39BCFBACA9FQ33392860-37A4E423-76D3-455C-9CAD-11C341A1693DQ33393692-4F0E28C2-505F-4F79-ACEA-8E204220E669Q33397359-9D13A436-A1A3-4888-B290-ABDC786DD271Q33435357-C11DA406-44DC-42A8-AC71-94705A2A75A0Q33556350-D1026159-527A-424C-9CB0-C98C621ABA14Q33891915-6F3413D9-4EA4-4CA3-908C-DC8AE142EFC2Q33894433-1AA693FD-293D-41D2-B770-6048ABFDBD29Q33911981-68788081-CF9B-4494-A7D4-C81D3BD87337Q34207558-4F4C565D-DE53-4E95-967B-01A68E07E737Q34262668-94C76A89-1D9B-4283-9681-9EBBFDDC2CD4Q34285711-D8C3A8DC-0327-4D59-A164-D829BB19BEF8Q34326655-BDAFE3A5-D368-4312-B59D-11A00D989623Q34381344-CC95F4E7-D95C-4749-A4D1-E13948435B38Q34437785-84D9B975-620A-4EFD-BB11-882A906BC9F5Q34469002-708D8CE4-9EB1-4B5F-80E8-D0339299F5CAQ34635335-55172BDE-CA43-42C1-B53B-512071CF8E16Q34638063-9CD62B1E-FFD3-49E8-95C1-7CEDB73505CDQ34694544-2A97BB74-A9A7-4EC6-BC16-4437B0B89C56Q34906214-E9093052-CB2D-41CB-BF6E-EF77EE73FEA9
P2860
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Comparative pharmacodynamics a ...... xa inhibitors in development.
@ast
Comparative pharmacodynamics a ...... xa inhibitors in development.
@en
Comparative pharmacodynamics a ...... xa inhibitors in development.
@nl
type
label
Comparative pharmacodynamics a ...... xa inhibitors in development.
@ast
Comparative pharmacodynamics a ...... xa inhibitors in development.
@en
Comparative pharmacodynamics a ...... xa inhibitors in development.
@nl
prefLabel
Comparative pharmacodynamics a ...... xa inhibitors in development.
@ast
Comparative pharmacodynamics a ...... xa inhibitors in development.
@en
Comparative pharmacodynamics a ...... xa inhibitors in development.
@nl
P2093
P1476
Comparative pharmacodynamics a ...... xa inhibitors in development.
@en
P2093
Bengt I Eriksson
Daniel J Quinlan
Jeffrey I Weitz
P356
10.2165/0003088-200948010-00001
P577
2009-01-01T00:00:00Z
P5875
P6179
1046841512